Concord Biotech Ltd.
NSE: CONCORDBIOConcord Biotech Ltd.: A 30-second snapshot
Concord Biotech trades at ₹1,061.3, down 30.78% over the past year and 50.65% from its 52-week high, with the current price sitting 20.9% below the 200-DMA of ₹1,343.28. The company reported FY2026 revenue decline of 12% with both 5-year revenue growth (-24.1%) and 5-year earnings growth (-36.8%) in contraction territory. Trailing PE of 42.78x contrasts with a forward PE of 22.30x, reflecting analyst expectations of a material earnings recovery that has not yet appeared in trailing results.
P/E
42.8
Forward P/E
22.3
ROE
+13.5%
Debt / Equity
0.12
Profit Margin
+24.7%
Div. Yield
+1.0%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
51/100
News
6 headlines · 2 positive · 0 negative
Concord Biotech Limited Recommends Dividend for the Financial Year Ended March 31, 2026 - marketscreener.com
marketscreener.com
CONCORDBIO: FY 2026 delivered solid growth, a Rs. 7.55 dividend, and a strategic acquisition, despite regulatory impacts - TradingView
TradingView
CONCORDBIO: Revenue declined 12% in FY 2026, but strong growth and margin improvement are expected in FY 2027 - TradingView
TradingView
Transcript : Concord Biotech Limited, Q4 2026 Earnings Call, Jun 01, 2026 - marketscreener.com
marketscreener.com
CONCORDBIO: Revenue and profit declined in FY 2026, but strong growth and margin recovery are expected in FY 2027 - TradingView
TradingView
Recent context
- ·Q4 FY2026 earnings call transcripts (June 1, 2026) and analyst notes cite regulatory impacts as the primary driver of FY2026 revenue decline of approximately 12%, with management commentary pointing to recovery expectations for FY2027.
- ·Concord Biotech announced a strategic acquisition during FY2026 alongside a dividend recommendation of ₹7.55 for the financial year ended March 31, 2026, per company disclosure dated May 29, 2026.
- ·Multiple analyst notes published around the Q4 results characterise FY2026 as a trough year for revenue and profit, with FY2027 growth and margin improvement described as expected outcomes — these projections are not yet validated by reported results.
Strengths
- +Debt-to-equity of 0.115 is low relative to the pharma sector, and the debt trend is flagged as falling, indicating a strengthening balance sheet position.
- +FCF was positive in 4 of the available persistence years with a consistency score of 98, suggesting the business has generated cash even during a period of earnings decline.
- +Profit margin of 24.73% is notable for a pharma company, and a dividend of ₹7.55 per share was recommended for FY2026 with a trailing yield of approximately 1.02%.
- +Forward PE of 22.30x versus trailing PE of 42.78x — a compression of approximately 48% — implies analyst expectations of a substantial earnings step-up in the coming year if the regulatory impacts cited in recent earnings commentary are resolved.
Weaknesses
- −5-year earnings growth of -36.8% and 5-year revenue growth of -24.1% reflect multi-year deterioration in both top-line and bottom-line, with earnings contracting faster than revenue.
- −Stock is 50.65% below its 52-week high and 20.9% below its 200-DMA, with the 1-year price return at -30.78%, indicating sustained and significant price underperformance against its own history.
- −Quality score of 30 ranks 4th of 6 sector peers (sector range 17–59), and ROE of 13.54% ranks 4th of 6 comparators, placing the company in the lower half of the peer group on both dimensions.
- −Trailing PE of 42.78x remains above peers Cipla (28.93x) and Dr. Reddys (25.64x) despite multi-year earnings contraction — the current multiple embeds an earnings recovery assumption that has yet to materialise.
Open questions
- ?Does the 5-year FCF persistence (4 of available years positive, consistency score 98) reflect a structural cash-generation advantage, or does it mask non-cash revenue recognition that explains the gap between FCF and declining reported earnings?
- ?What specific regulatory actions impacted FY2026 revenue, and how does the timeline and probability of resolution compare to the implied recovery already priced into the 22.30x forward PE?
- ?At what pace has the D/E ratio been declining, and does the current 0.115 level provide meaningful financial flexibility to fund the strategic acquisition announced during FY2026 without straining the balance sheet?
- ?How does Concord Biotechs product mix and geographic revenue split compare to peers such as Sun Pharma (quality score 59) and Apollo Hospitals (ROE 21.5%), and does the peer group selection reflect the companys actual competitive context?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| CONCORDBIO | Concord Biotech Ltd.You're viewing | 42.8 | +13.5% | 30 |
| Industry avg | across 5 peers | 43.2 | +14.8% | 36 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 37.5 | +14.7% | 59 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 60.1 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 63.5 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 28.9 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 25.6 | +11.8% | 17 |
Technical state
Current price
₹1,061.30
SMA 50
₹1,094.61
SMA 200
₹1,343.28
RSI (14)
40.6 (neutral)
From 52w high
-50.6%
1Y return
-30.8%
3M return
-1.4%
50-DMA
Below
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highStock has declined 50.65% from its 52-week high and trades at ₹1,061.3, which is 20.9% below the 200-DMA of ₹1,343.28 and 3.1% below the 50-DMA of ₹1,094.61. The 1-year price change is -30.78%, with the stock below both moving averages.
- high5-year revenue growth of -24.1% and 5-year earnings growth of -36.8% indicate sustained top-line and bottom-line contraction over the measurement period, with earnings declining faster than revenue.
- mediumTrailing PE of 42.78x is above pharma peers Cipla (28.93x) and Dr. Reddys (25.64x) despite a 5-year earnings decline of 36.8%. The forward PE of 22.30x implies a significant earnings recovery that is not yet reflected in trailing results.
- mediumQuality score of 30 ranks 4th of 6 sector peers (range 17–59); ROE of 13.54% ranks 4th of 6, below sector peers Apollo Hospitals (21.5%) and Sun Pharma (14.72%).
- lowAnalyst consensus rating is null (unavailable) despite 5 analysts covering the stock. Peer priceChange1Y data is null for all 5 comparators, limiting relative price-performance benchmarking. News total is 6 items (sparse).
Cross-section contradictions
- FCF was positive in 4 of the available years with a consistency score of 98 and a falling debt trend (D/E 0.115), yet 5-year earnings growth is -36.8% and 5-year revenue growth is -24.1% — the divergence between FCF persistence and declining reported earnings and revenue warrants scrutiny of accrual items or structural cost shifts.
- Price is 50.65% below the 52-week high with RSI at 40.63 while all 6 available news items carry neutral or positive sentiment (2 positive, 4 neutral, 0 negative) — the severity of the price decline is not reflected in the available news sentiment record.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Jun 2026 · rotates through NIFTY 500 every ~5 days